PDCD1LG2 and neoplasm: The expression level of PD-L2 was higher in tumor tissues than in normal tissues (p < 0.05, Figure 6a), and it was markedly higher in people with a high risk score in both the TCGA and GEO dataset (p < 0.05, Figure 6c–f), suggesting that people in the high-risk group will benefit less from immune checkpoint inhibitors (ICIs).